Altimmune (ALT) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neurogene (NGNE) has outperformed Altimmune (ALT) over the past year, gaining 2.6% versus a loss of 32.3%. Over five years, ALT leads with a -77.9% price change compared with -81.6% for NGNE. Neurogene is the larger company by market cap ($530.3 million vs $505.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | NGNE |
|---|---|---|
| Share price | $2.60 | $26.50 |
| Market cap | $505.75M | $530.30M |
| 1-day change | -2.26% | +2.44% |
| YTD return | -26.32% | +28.64% |
| 1-year return | -32.32% | +2.59% |
| 5-year return | -77.85% | -81.65% |
| EPS (TTM) | $-0.76 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $43.66 |
| 52-week low | $2.55 | $15.93 |
| Distance from 52-week high | -59.63% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +558.08% | +193.89% |
| Average volume | 4.21M | 247.13K |
| Shares outstanding | 194.52M | 20.01M |
| Employees | 57 | 131 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed ALT by 34.9 percentage points over the past year.
- The two companies sit in different sectors: Altimmune in Health Care and Neurogene in Healthcare.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
ALT vs NGNE FAQ
Which is bigger, Altimmune or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $530.30M compared with $505.75M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or NGNE?
NGNE returned +2.59% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Neurogene in the same industry?
No. Altimmune is in the Health Care sector, while Neurogene is in Healthcare.